Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Aug. 31, 2020
Aug. 31, 2019
Aug. 31, 2020
Aug. 31, 2019
Research and development expenses $ 2,749,222 $ 970,213 $ 4,229,810 $ 1,968,074
Stock Options        
Antidilutive securities     1,590,470 1,657,081
Restricted Stock Units        
Antidilutive securities     4,313,750 4,419,753
Warrants        
Antidilutive securities     4,884,331 5,040,267